| For: | Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, Mehta PD, Brar AS, Sohal A, Goyal MK, Hatwal J, Batta A. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes 2026; 17(2): 113149 [PMID: 41696109 DOI: 10.4239/wjd.v17.i2.113149] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i2/113149.htm |
| Number | Citing Articles |
| 1 |
Ileana Pantea, Angela Repanovici, Hamza Islam. Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/1853763
|
| 2 |
Nebyu Yonas Shanka, Chavdar S. Pavlov, Taisiia A. Turankova, Temesgen Tesfaye Ajabo, Leul Mekonnen Nigatu, Biniyam Esayas Dana, Poorani Gurumallesh Prabu. Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study. BioMed Research International 2026; 2026(1) doi: 10.1155/bmri/1662756
|
| 3 |
Fernanda M. Martínez-Díaz, Elsie A. Jiménez-Cuevas, Mariana M. Ramírez-Mejía, Sarai Gómez-Camacho, Nahum Méndez-Sánchez. The interplay of insulin resistance, glycemic variability, and metabolic dysfunction-associated steatotic liver disease. Exploration of Digestive Diseases 2026; 5 doi: 10.37349/edd.2026.1005115
|
